PHASEBIO PHARMACEUTICALS INC's ticker is PHAS and the CUSIP is 717224109. A total of 59 filers reported holding PHASEBIO PHARMACEUTICALS INC in Q4 2020. The put-call ratio across all filers is - and the average weighting 0.0%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q3 2022 | $2,000 | -86.7% | 10,603 | -57.9% | 0.00% | – |
| Q2 2022 | $15,000 | – | 25,203 | +9861.7% | 0.00% | – |
| Q1 2022 | $0 | – | 253 | +130.0% | 0.00% | – |
| Q4 2021 | $0 | -100.0% | 110 | -98.6% | 0.00% | -100.0% |
| Q3 2021 | $26,000 | +100.0% | 8,122 | +127.8% | 0.00% | – |
| Q2 2021 | $13,000 | 0.0% | 3,565 | -3.5% | 0.00% | – |
| Q1 2021 | $13,000 | -60.6% | 3,696 | -62.6% | 0.00% | -100.0% |
| Q4 2020 | $33,000 | -43.1% | 9,886 | -40.7% | 0.00% | 0.0% |
| Q3 2020 | $58,000 | +314.3% | 16,665 | +444.6% | 0.00% | 0.0% |
| Q2 2020 | $14,000 | +366.7% | 3,060 | +271.4% | 0.00% | – |
| Q1 2020 | $3,000 | +50.0% | 824 | +120.9% | 0.00% | – |
| Q4 2019 | $2,000 | -71.4% | 373 | -78.1% | 0.00% | – |
| Q3 2019 | $7,000 | +16.7% | 1,702 | +299.5% | 0.00% | – |
| Q2 2019 | $6,000 | +500.0% | 426 | +4.4% | 0.00% | – |
| Q4 2018 | $1,000 | – | 408 | – | 0.00% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| Johnson & Johnson Innovation - JJDC, Inc. | 1,607,044 | $5,400,000 | 0.70% |
| NEA Management Company, LLC | 6,643,704 | $22,323,000 | 0.59% |
| DAFNA Capital Management LLC | 320,542 | $1,077,000 | 0.32% |
| Platform Technology Partners | 141,025 | $474,000 | 0.23% |
| Parkman Healthcare Partners LLC | 110,547 | $371,000 | 0.10% |
| Rock Springs Capital Management LP | 1,314,374 | $4,416,000 | 0.09% |
| GSA CAPITAL PARTNERS LLP | 140,341 | $472,000 | 0.08% |
| SABBY MANAGEMENT, LLC | 65,000 | $218,000 | 0.04% |
| Virtu Financial LLC | 28,821 | $97,000 | 0.01% |
| BRIDGEWAY CAPITAL MANAGEMENT, LLC | 127,600 | $429,000 | 0.01% |